JP6861301B2 - 移植片拒絶の予防に使用するための抗ｃｄ４０抗体 - Google Patents

移植片拒絶の予防に使用するための抗ｃｄ４０抗体 Download PDF

Info

Publication number
JP6861301B2
JP6861301B2 JP2019562323A JP2019562323A JP6861301B2 JP 6861301 B2 JP6861301 B2 JP 6861301B2 JP 2019562323 A JP2019562323 A JP 2019562323A JP 2019562323 A JP2019562323 A JP 2019562323A JP 6861301 B2 JP6861301 B2 JP 6861301B2
Authority
JP
Japan
Prior art keywords
antibody
cfz533
dose
seq
transplant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019562323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519634A (ja
Inventor
エスピー，パスカル
ハラルドソン，ボリエ
ラッシュ，ジェイムズ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2020519634A publication Critical patent/JP2020519634A/ja
Priority to JP2021012521A priority Critical patent/JP2021113190A/ja
Application granted granted Critical
Publication of JP6861301B2 publication Critical patent/JP6861301B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019562323A 2018-04-13 2019-04-11 移植片拒絶の予防に使用するための抗ｃｄ４０抗体 Expired - Fee Related JP6861301B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021012521A JP2021113190A (ja) 2018-04-13 2021-01-28 移植片拒絶の予防に使用するための抗ｃｄ４０抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862657172P 2018-04-13 2018-04-13
US62/657,172 2018-04-13
EP18208332.9 2018-11-26
EP18208332 2018-11-26
PCT/IB2019/052976 WO2019198019A1 (en) 2018-04-13 2019-04-11 Anti-cd40 antibodies for use in prevention of graft rejection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021012521A Division JP2021113190A (ja) 2018-04-13 2021-01-28 移植片拒絶の予防に使用するための抗ｃｄ４０抗体

Publications (2)

Publication Number Publication Date
JP2020519634A JP2020519634A (ja) 2020-07-02
JP6861301B2 true JP6861301B2 (ja) 2021-04-21

Family

ID=66542473

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019562323A Expired - Fee Related JP6861301B2 (ja) 2018-04-13 2019-04-11 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
JP2021012521A Pending JP2021113190A (ja) 2018-04-13 2021-01-28 移植片拒絶の予防に使用するための抗ｃｄ４０抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021012521A Pending JP2021113190A (ja) 2018-04-13 2021-01-28 移植片拒絶の予防に使用するための抗ｃｄ４０抗体

Country Status (13)

Country Link
US (2) US11780927B2 (https=)
EP (1) EP3774913A1 (https=)
JP (2) JP6861301B2 (https=)
KR (1) KR20200143718A (https=)
CN (1) CN111971307A (https=)
AU (1) AU2019252858A1 (https=)
BR (1) BR112020020277A2 (https=)
CA (1) CA3094600A1 (https=)
CL (1) CL2020002622A1 (https=)
IL (1) IL277828A (https=)
MX (1) MX2020010722A (https=)
TW (1) TW201943731A (https=)
WO (1) WO2019198019A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020225736A1 (en) * 2019-05-08 2020-11-12 Novartis Ag Anti-cd40 antibodies for use in treatment of t1dm and insulitis
CN116234909A (zh) * 2020-08-21 2023-06-06 上海药明生物技术有限公司 Cd40激动剂抗体和使用方法
WO2022090194A1 (en) * 2020-10-26 2022-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for assessing the area under the curve of an immunosuppressant and associated method and systems
EP4402174A1 (en) * 2021-09-17 2024-07-24 Novartis AG Methods for prevention of graft rejection in xenotransplantation
WO2025117849A1 (en) * 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025235683A1 (en) * 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
BRPI0417266B8 (pt) 2003-12-25 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo monoclonal, seu uso e composição farmacêutica
CN101014386A (zh) * 2004-04-27 2007-08-08 诺华疫苗和诊断公司 拮抗性抗－cd40单克隆抗体及其使用方法
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
BR112012024713B1 (pt) 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US11780977B2 (en) * 2020-08-10 2023-10-10 Dover Chemical Corporation Polymer compositions having an improved printable surface and related methods

Also Published As

Publication number Publication date
CL2020002622A1 (es) 2021-04-16
MX2020010722A (es) 2020-11-06
KR20200143718A (ko) 2020-12-24
JP2021113190A (ja) 2021-08-05
WO2019198019A1 (en) 2019-10-17
CA3094600A1 (en) 2019-10-17
JP2020519634A (ja) 2020-07-02
EP3774913A1 (en) 2021-02-17
US11780927B2 (en) 2023-10-10
US20240287198A1 (en) 2024-08-29
AU2019252858A1 (en) 2020-10-08
IL277828A (en) 2020-11-30
CN111971307A (zh) 2020-11-20
TW201943731A (zh) 2019-11-16
BR112020020277A2 (pt) 2021-01-19
US20210079107A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
JP6861301B2 (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
US12465635B2 (en) Methods of treating inflammatory arthritis using secukinumab
US20250206833A1 (en) Anti-CD40 Antibodies for Use in Treatment of Sjogren's Syndrome
US20220195061A1 (en) Anti-cd40 antibodies for use in treatment of tidm and insulitis
JP2021181439A (ja) 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体
RU2790558C2 (ru) Антитела к cd40 для применения в лечении синдрома шегрена
HK40010039A (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK40083901A (en) Methods of treating rheumatoid arthritis using il-17 antagonists
HK40040628A (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK40035240A (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK40061520A (en) Pharmaceutical compositions comprising secukinumab
HK40035240B (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK1229257B (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191111

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191111

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210205

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210329

R150 Certificate of patent or registration of utility model

Ref document number: 6861301

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees